Insiders Updates
Astrazeneca plc ADR (AZN) Becoming More Attractive for Investors
Following these proceedings, UBS upgraded its Astrazeneca plc ADR [AZN] rating to a Neutral from a a Sell in a
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.